Alzheimer’s ‘advance’ stalls: why a highly publicized drug faces delays in approval | Dementia | Top Vip News
[ad_1] YoIt was heralded in newspaper articles as a “breakthrough,” a “turning point,” and a “game changer” for Alzheimer’s disease. Some experts went so far as to call the drug donanemab the “beginning of the end” of this debilitating disease. In May 2023, the pharmaceutical company Eli Lilly published data from a clinical trial that … Read more